Mar 24, 2006 - Janindra Warusavitarne. Palaniappan Ramanathan. Anthony Kaufman. Bruce G. Robinson. Margaret Schnitzler. Accepted: 7 December 2005.
Colorectal cancer is a disease of the elderly, and affects the younger ... patients who had colorectal cancer from January 1994 to March 1999 at Mansoura Uni-.
Aug 26, 2009 - profile of mismatch repair (MMR) defects in Iranian colorectal cancer patients by using immunohistochemical ..... cancer (Lynch syndrome).
Jun 25, 2015 - Wilson TR, Alexander DJ, Kind P (2006) Measurement of health- ... Phipps E, Braitman LE, Stites S, Leighton JC (2008) Quality of life.
Dec 29, 2010 - Abstract. Purpose Panitumumab monotherapy is approved for chemotherapy-refractory wild-type KRAS metastatic colorec- tal cancer (mCRC).
Apr 7, 2012 - associated in colon cancer-1 (MACC1) and demonstrated its important role for ... well as metastasis in several mouse models. Here we report.
Aug 30, 2013 - Keywords: DNA methylation, Septin 9, Colorectal cancer, Adenoma, Epithelial cells, ... deleted in sporadic ovarian tumors [5] or amplified in.
Apr 12, 2008 - Age and examination year adjusted risk ratio of colorectal cancer among men within the highest quintile of alcohol consumption was 4.4.
J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2010 11(12):923-930. 923. Colorectal ... Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology).
May 29, 2015 - University Hospitals Bristol NHS Foundation Trust, Bristol, UK. ... 4Department of General Surgery, North Bristol NHS Trust, Bristol, UK. 5Severn.
Mar 26, 2010 - The use of local excision to treat T2 and NX rectal cancers is highly ... of choice in these cases is therefore total mesorectal excision (124).
Clin Transl Oncol (2010) 12:456 DOI 10.1007/s12094-010-0535-3
Colorectal Cancer OncoGuia Paula Manchon Walsh · Josep M. Borràs · Tàrsila Ferro · Josep Alfons Espinàs on behalf of the Colorectal Cancer OncoGuia Group*
In the text there was a mistake. The correct text is: The surgical treatment of choice for patients with high-risk T1, T2, and NX rectal cancer is total mesorectal excision. [S] The use of local excision to treat T2 and NX rectal cancers is highly controversial as lymph node metastasis can occur in up to 28% of cases (123). The treatment of choice in these cases is therefore total mesorectal excision (124). An alternative proposed by the NCCN (23) and classified as a category 2B recommendation (lower-level evidence and nonuniform consensus) is the administration of chemoradiotherapy after local surgery. Nonetheless, it should be borne in mind that the efficacy of this concomitant treatment regimen over total mesorectal excision in terms of local recurrence and survival needs to be demonstrated in clinical trials. [NCCN]
The original version of the article can be found in: Clin Trans Oncol (2010) 12:188-210 DOI 10.1007/s12094-010-0489-5
